Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 9:35 PM
Ignite Modification Date: 2025-12-24 @ 9:35 PM
NCT ID: NCT00974532
Eligibility Criteria: Inclusion Criteria: * Men and women 18 years of age or greater and able to comply with the study protocol. * eGFR within appropriate target ranges (15-40 ml/min/m² for late stage CKD stage 3 stage 4, and eGFR \> 60 ml/min/m² for normal subjects) * Stable kidney function defined as an eGFR which remains within a 10ml/min range over a 3 to 6 month period prior to study enrollment. This will be determined from historical laboratory data. * Willing to follow study protocol * Have a level of understanding and willingness to cooperate with all visits and procedures as described by the study personnel * Overall stable medical condition, defined as no malignancy, metabolic condition or gastrointestinal condition that would make it difficult to comply with the study protocol and complete both dietary study periods * Able to read the consent form and provide informed consent. * Serum calcium and phosphorus within the normal range off of vitamin D analogues, calcium supplements, and phosphate binders for 1 month. Exclusion Criteria: * 1\. Age less than 18 years * Are pregnant, plan on becoming pregnant during the study period, or breast-feeding, if female. * Patient declines participation. * GI malabsorption, short bowel syndrome, frequent vomiting, or gastroparesis. * Subject receiving synthetic parathyroid hormone, glucocorticoids, calcitonin or bisphosphonates.
Healthy Volunteers: True
Sex: ALL
Minimum Age: 18 Years
Study: NCT00974532
Study Brief:
Protocol Section: NCT00974532